HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.

AbstractPURPOSE:
To assess the clinical profile and prognostic factors in patients with adenosquamous carcinoma (ASC) of the head and neck treated by surgery and/or radiation therapy with or without chemotherapy.
METHODS:
Data from 20 patients with stage I-II (n = 4), III (n = 5), or IVA (n = 11) head and neck ASC, treated between 1989 and 2010 were collected in a retrospective multicenter Rare Cancer Network study. Surgery was performed in 16 patients. Seventeen patients received combined modality treatment.
RESULTS:
After a median follow-up of 15.5 months, 12 patients recurred. The 3-year and median overall survival, disease-free survival (DFS), and loco-regional control were 52% and 39 months, 32% and 12 months, and 47% and 33 months respectively. In multivariate analysis, DFS was negatively influenced by the presence of extracapsular extension and advanced stage.
CONCLUSION:
Overall prognosis of locoregionally advanced ASC remains poor. However, early stage ASC patients managed with combined modality treatment may have prolonged DFS.
AuthorsUlrike Schick, Marc Pusztaszeri, Michael Betz, Pirus Ghadjar, Candan Demiroz, Johannes H A M Kaanders, Mahmut Ozsahin
JournalOral surgery, oral medicine, oral pathology and oral radiology (Oral Surg Oral Med Oral Pathol Oral Radiol) Vol. 116 Issue 3 Pg. 313-20 (Sep 2013) ISSN: 2212-4411 [Electronic] United States
PMID23850369 (Publication Type: Journal Article, Multicenter Study, Review)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Adenosquamous (mortality, pathology, therapy)
  • Disease-Free Survival
  • Female
  • Head and Neck Neoplasms (mortality, pathology, therapy)
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (mortality, pathology, therapy)
  • Netherlands (epidemiology)
  • Prognosis
  • Proportional Hazards Models
  • Rare Diseases (epidemiology)
  • Retrospective Studies
  • Survival Rate
  • Switzerland (epidemiology)
  • Turkey (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: